Cynomolgus / Rhesus PD-L1 / B7-H1 / CD274 Protein (His Tag)

Catalog Number: **90251-C08H**

Sino Biological Inc.
Biological Solution Specialist

General Information

Gene Name Synonym:

B7-H; B7-H1; B7H1; PD-L1; PDCD1L1; PDCD1LG1; PDL1; A530045L16Rik; B7h1; Pdcd1l1; Pdcd1lg1; Pdl1

Protein Construction:

A DNA sequence encoding the cynomolgus/rhesus CD274 (F6VEW6) (Met1-Thr239) was expressed with a polyhistidine tag at the C-terminus. Cynomolgus and Rhesus CD274 sequences are identical.

Source: Cynomolgus

Expression Host: Human Cells

QC Testing

Purity: > 95 % as determined by SDS-PAGE

Bio Activity:

Measured by its binding ability in a functional ELISA. Immobilized Cynomolgus CD274-His at 10 μg/ml (100 μl/well) can bind Cynomolgus PDCD1-Fc (Cat: 90311-C02H), The EC_{50} of Cynomolgus PDCD1-Fc (Cat: 90311-C02H) is 1.0-2.3μg/ml.

Endotoxin:

< 1.0 EU per μg of the protein as determined by the LAL method

Stability:

Samples are stable for up to twelve months from date of receipt at -70 ℃

Predicted N terminal: Phe 19

Molecular Mass:

The recombinant cynomolgus/rhesus CD274 comprises 232 amino acids and has a calculated molecular mass of 26.7 KDa. The apparent molecular mass of it is approximately 37 KDa in SDS-PAGE.

Formulation:

Lyophilized from sterile PBS, pH 7.4.

Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA. Please contact us for any concerns or special requirements.

Usage Guide

Storage:


Store it under sterile conditions at -20℃ to -80℃ upon receiving. Recommend to aliquot the protein into smaller quantities for optimal storage.

Avoid repeated freeze-thaw cycles.

Reconstitution:

Detailed reconstitution instructions are sent along with the products.

SDS-PAGE:



Protein Description

Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. PD-L1/B7-H1 is a member of the growing B7 family of immune molecules and this protein contains one V-like and one C-like Ig domain within the extracellular domain, and together with PD-L2, are two ligands for PD1 which belongs to the CD28/CTLA4 family expressed on activated lymphoid cells. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.

References

1.Iwai Y, *et al.* (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 99(19): 12293-7.
2.Ghebeh H, *et al.* (2006) The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia. 8(3): 190-8.
3.Salih HR, *et al.* (2006) The role of leukemia-derived B7-H1 (PD-L1) in tumor-T-cell interactions in humans. Exp Hematol. 34(7): 888-94.